ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Dat	e: 31. august 2023		
You	Ir name: Louis Jean Lep	etit Thomsen	
Ma	nuscript title: Kuta	n depigmentering og su	bkutan atrofi efter peritendinøs
Ma	nuscript number (if know	n):	
are r third comi	elated to the content of y parties whose interests n mitment to transparency a	our manuscript. "Related" hay be affected by the con	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a ndicate a bias. If you are in doubt about whether to ou do so.
	following questions apply uscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
perta antih	ains to the epidemiology on the second of th	of hypertension, you shoul even if that medication is r	defined broadly. For example, if your manuscript d declare all relationships with manufacturers of not mentioned in the manuscript.
		oport for the work reporter r disclosure is the past 36	d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial pla	The state of the s	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	
			Click TAB in last row to add extra rows
Tim	ne frame: past 36 months	MADELLAS DE	
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	

4	Consulting fees	⊠ None		
5	Payment or honoraria for	⊠ None		
"	lectures, presentations, speakers bureaus, manuscript writing or educational events	M Notice		
6	Payment for expert	⊠ None		
	testimony			
_		1		
7	Support for attending	⊠ None		
	meetings and/or travel			
		I		
8	Patents planned, issued or	⊠ None		
	pending			
9	Participation on a Data	⊠ None		
,	Participation on a Data Safety Monitoring Board	None		
	or Advisory Board			
	or Advisory Bodia			
10	Leadership or fiduciary	⊠ None		
	role in other board,			
	society, committee or advocacy group, paid or unpaid			
	1/	·		
11	Stock or stock options	⊠ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	57.4		
12		⊠ None		
13	Other financial or non- financial interests	⊠ None		
		ES HONG		

Please place an "X" next to the following statement to indicate your agreement:

🖾 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

	Your name: Samir Ejam		
	Manuscript title: Ku	tan denigmentering og	Pur la la character de la constant d
	Manuscript number (if kno	wn):	subkutan atrofi efter peritendings
cc lis	ird parties whose interests mmitment to transparency t a relationship/activity/int	may be affected by the co and does not necessarily erest, it is preferable that	
m	e following questions apply nuscript only.	y to the author's relations	hips/activities/interests as they relate to the <u>current</u>
n i	tem #1 below, report all su	nnort for the	ld declare all relationships with manufacturers of not mentioned in the manuscript. ed in this manuscript without time limit. For all
-	er items, the time frame fo	Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your
· ir	ne frame. Since the initial pla	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your
Γιr	he frame. Since the initial pla All support for the present	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your
ir.	ne frame. Since the initial pla All support for the present manuscript (e.g., funding	Name all entities with whom you have this relationship or indicate none (edd rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your
Γιr	All support for the present manuscript (e.g., funding, provision of study materials, medical writing	Name all entities with whom you have this relationship or indicate none (edd rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your
Γιr	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	Name all entities with whom you have this relationship or indicate none (edd rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your
Γιr	All support for the present manuscript (e.g., funding, provision of study materials, medical writing	Name all entities with whom you have this relationship or indicate none (edd rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your
· ir	All support for the initial pla All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (edd rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your
Γισ	All support for the initial pla All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (edd rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your
Tir.	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (edd rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the initial pla All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (edd rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your
	All support for the initial pla All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (edd rows as needed) naing of the work None	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (edd rows as needed) nning of the work	Specifications/Comments (e.g., if payments were made to you or to your institution)
Γι <i>σ</i>	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated)	Name all entities with whom you have this relationship or indicate none (edd rows as needed) naing of the work None	Specifications/Comments (e.g., if payments were made to you or to your institution)

	ulting fees	4	
	ent or honoraria for	5	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
		6	
	Payment for expert testimony		
	t for attending		
	gs and/or travel		
	planned, issued or	T	
		pending	
	ation on a Data	Participation on a Data	
	onitoring Board Dry Board	Safety Monitoring Board or Advisory Board	
	ip or fiduciary her board,	L	
	Ommittee or	SC	
	group, paid or	ui	
	tock options	St	
	equipment,	Re	
	fts or other	wri	
	ncial or non-	Other financial or non-	
	terests	fina	
	drugs, medical fts or other	wri ser	

Please place an "X" next to the following statement to indicate your agreement:

☑ I certify that I have answered every question and have not altered the wording of any of the IMPORTANT for Ugeskrift for Læger & Danish Medical Journal questions on this form.

Please save/export the filled Inform as PDF before submitting it to Ugeskrift for Læger or Danish

ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Vour name: Anne Birgitte Simonsen				
Manuscript title	: Kutan depigmentering og subkutan atrofi efter peritendinøs			
Manuscript nun	nber (if known):			
are related to the	transparency, we ask you to disclose all relationships/activities/interests listed below that content of your manuscript. "Related" means any relation with for-profit or not-for-profit se interests may be affected by the content of the manuscript. Disclosure represents a			

commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial plan	ning of the work	
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	
		Click TAB in last row to add extra ro

e frame: past 36 months	
Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None
Royalties or licenses	⊠ None
	any entity (if not indicated in item #1 above).

manuscript only.

4	Consulting fees	□ None			
		Galderma			
		Abbvie			
5	Payment or honoraria for	□ None			
_	lectures, presentations, speakers bureaus, manuscript writing or educational events	Leo Pharma	Lecture		
		Leo Pharma	Lecture		
	Cudational events				
6	Payment for expert	⊠ None			
	testimony				
7	Commant for attending				
/	Support for attending meetings and/or travel	□ None			
	meetings and/or traver	Leo Pharma	Congress fee		
8	Patents planned, issued or	⊠ None			
	pending				
	_				
9	Participation on a Data	⊠ None			
	Safety Monitoring Board				
	or Advisory Board				
10	Leadership or fiduciary	⊠ None			
10	role in other board,	IZI MOHE			
	society, committee or				
	advocacy group, paid or				
	unpaid				
11	Stock or stock options	⊠ None			
12	Descint of antiques				
12	Receipt of equipment, materials, drugs, medical	⊠ None			
	writing, gifts or other services				
	wat riwad				
13	Other financial or non-	⊠ None			
	financial interests				

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.